A clutch of new dipeptidyl peptidase-4 (DPP-4) inhibitors including LG Life Sciences Ltd's gemigliptin and Dong-A ST Co. Ltd 's evogliptin have either just hit the Indian market or are on the horizon, amid what some industry watchers say are early signs of a volume shake-up in the highly competitive gliptins market.
First the new entrant. Last month Sanofi quietly launched gemigliptin on the Indian market, opening up another prong in its quest for dominance in the diabetes segment in the country.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
